Lilly says no higher offer for SGX

Eli Lilly says it won't be sweetening its offer for SGX Pharmaceuticals. The company says its bid of $3 a share, which had doubled the stock's value, was its best and final offer. Shareholders vote August 20. Report

Suggested Articles

Biogen biologics plant in Denmark
Biotech

Biogen nabs speedy FDA review for controversial Alzheimer’s drug

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

by Amirah Al Idrus
illustrates the journey to CFO
Biotech

Chutes & Ladders—Alexion names first chief diversity officer

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

by Eric Sagonowsky
Pancreatic islets
Research

How a protein promotes pancreatic cancer metastasis

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.

by Angus Liu